VIBRA-TABS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).

How it works

Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.

What the body does with it

Metabolism	Primarily hepatically metabolized; no specific major enzyme pathway identified, but thought to involve oxidative metabolism.
Excretion	Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Half-life	Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Protein binding	60-80% bound to plasma proteins, primarily albumin.
Volume of Distribution	1.3-1.8 L/kg; indicates extensive tissue penetration (e.g., lung, prostate, bile).
Bioavailability	Oral: 95-100% (doxycycline hyclate); food decreases absorption by 20% (no significant effect with Vibra-Tabs formulation).
Onset of Action	Oral: 30-60 minutes (therapeutic serum levels at 1-2 hours).
Duration of Action	24 hours (maintained by twice-daily dosing).

Classification & Brands

Dosing & administration

100 mg orally twice daily on day 1, then 100 mg orally once daily

Dosage form	TABLET
Renal impairment	CrCl >50 mL/min: no adjustment; CrCl 10-50 mL/min: 100 mg every 24 hours; CrCl <10 mL/min: 100 mg every 36 hours
Liver impairment	No adjustment required for mild to moderate hepatic impairment; not recommended in severe hepatic impairment (Child-Pugh C)
Pediatric use	≥8 years and >45 kg: 100 mg orally every 12 hours on day 1, then 100 mg orally once daily; ≤45 kg: 4.4 mg/kg on day 1, then 2.2 mg/kg orally once daily; maximum 100 mg/day
Geriatric use	Use lowest effective dose; monitor renal function as clearance may be reduced; no specific dose adjustment based on age alone

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).

Breastfeeding	Tetracycline is excreted into breast milk in low concentrations (M/P ratio approximately 0.5–0.8). The American Academy of Pediatrics considers use compatible with breastfeeding, but theoretical risk of teeth discoloration and bone growth suppression exists. Use alternative if possible.
Teratogenic Risk	Tetracycline (active ingredient in Vibra-Tabs) crosses the placenta. First trimester: Avoid due to possible teratogenicity (limb anomalies, neural tube defects) from animal studies, though human data limited. Second and third trimesters: Contraindicated; causes permanent yellow-gray-brown discoloration of deciduous teeth, enamel hypoplasia, and reversible skeletal growth retardation.

Warnings & precautions

■ FDA Black Box Warning

Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia. Should not be used in this age group unless other drugs are likely ineffective or contraindicated.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to tetracyclines or any component.","Pregnancy (especially second and third trimesters).","Lactation (may be excreted in breast milk).","Children under 8 years of age (tooth discoloration).","Severe hepatic impairment.","Concomitant use with isotretinoin (risk of pseudotumor cerebri)."]

Clinical Precautions

Precautions

["Photosensitivity manifested by exaggerated sunburn reaction.","May cause pseudomembranous colitis due to Clostridium difficile overgrowth.","Hepatotoxicity has been reported; use with caution in patients with hepatic impairment.","Renal toxicity: do not use in patients with impaired renal function unless necessary; may increase BUN due to anti-anabolic effect.","Overgrowth of non-susceptible organisms including fungi.","May cause benign intracranial hypertension (pseudotumor cerebri)."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VIBRA-TABS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).

How it works

Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.

What the body does with it

Metabolism	Primarily hepatically metabolized; no specific major enzyme pathway identified, but thought to involve oxidative metabolism.
Excretion	Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Half-life	Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Protein binding	60-80% bound to plasma proteins, primarily albumin.
Volume of Distribution	1.3-1.8 L/kg; indicates extensive tissue penetration (e.g., lung, prostate, bile).
Bioavailability	Oral: 95-100% (doxycycline hyclate); food decreases absorption by 20% (no significant effect with Vibra-Tabs formulation).
Onset of Action	Oral: 30-60 minutes (therapeutic serum levels at 1-2 hours).
Duration of Action	24 hours (maintained by twice-daily dosing).

Classification & Brands

Dosing & administration

100 mg orally twice daily on day 1, then 100 mg orally once daily

Dosage form	TABLET
Renal impairment	CrCl >50 mL/min: no adjustment; CrCl 10-50 mL/min: 100 mg every 24 hours; CrCl <10 mL/min: 100 mg every 36 hours
Liver impairment	No adjustment required for mild to moderate hepatic impairment; not recommended in severe hepatic impairment (Child-Pugh C)
Pediatric use	≥8 years and >45 kg: 100 mg orally every 12 hours on day 1, then 100 mg orally once daily; ≤45 kg: 4.4 mg/kg on day 1, then 2.2 mg/kg orally once daily; maximum 100 mg/day
Geriatric use	Use lowest effective dose; monitor renal function as clearance may be reduced; no specific dose adjustment based on age alone

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).

Breastfeeding	Tetracycline is excreted into breast milk in low concentrations (M/P ratio approximately 0.5–0.8). The American Academy of Pediatrics considers use compatible with breastfeeding, but theoretical risk of teeth discoloration and bone growth suppression exists. Use alternative if possible.
Teratogenic Risk	Tetracycline (active ingredient in Vibra-Tabs) crosses the placenta. First trimester: Avoid due to possible teratogenicity (limb anomalies, neural tube defects) from animal studies, though human data limited. Second and third trimesters: Contraindicated; causes permanent yellow-gray-brown discoloration of deciduous teeth, enamel hypoplasia, and reversible skeletal growth retardation.